Global Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market: Impact of COVID-19 and Forecast to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global RSV Vaccine and Antibody Pipeline Market: Analysis by End User, Type, Region, Size and Trends to 2028” report has been added to from ResearchAndMarkets.com offer.

The development of an RSV vaccine has made significant progress over the past ten years. The RSV Vaccines and Antibodies Market is expected to grow at a CAGR of 38.90% during the years 2024-2028.

As several vaccines and antibodies are close to their final stage of reading, commercialization and launch of some of them are expected by 2024. Estimates are made for the period of 2024 to 2028. Considering both the modalities (antibody and vaccine) targeting all three age groups, the global market for RSV vaccines and antibodies is expected to be worth US$2.56 billion in 2024, and reach US$9.53 billion in 2028.

Market Segmentation Analysis:

  • By Type: The report provides the bifurcation of the respiratory syncytial virus vaccines and antibodies market into two segments on the basis of type: vaccine and antibody. In 2024, the vaccines segment is expected to dominate the respiratory syncytial virus vaccines and antibodies market, accounting for 67.5% of the market, as several vaccine candidate trials are close to the final stage of reading and their launch is scheduled for soon. Adult vaccination may also help prevent RSV infection in children when a susceptible child is around vaccinated people, providing a localized herd immunity effect.

  • By end user: The report identifies two segments based on end user: adult and maternal and pediatric. The adult segment is expected to dominate the respiratory syncytial virus vaccines and antibodies market in 2024, with 59.08% market share. The rising incidence of RSV in older, immunocompromised adults has gained traction over the years, and several major players have begun adult vaccine and antibody trials, which is seen as a key factor in giving the adult segment a dominant part.

  • By Region: In the report, the global respiratory syncytial virus vaccines and antibodies market is segmented into three regions: US, Europe and Rest of the World. The United States is expected to dominate the market in 2024 by occupying almost half of the global market share. The most important factor driving the respiratory syncytial virus vaccines and antibodies market in the United States is the growing prevalence of RSV. Moreover, the presence of major players and good healthcare institutions in the region would drive the US respiratory syncytial virus vaccine and antibody market in the coming years. The European respiratory syncytial virus vaccines and antibodies market offers lucrative opportunities in the coming years.

COVID-19 impact analysis and way forward:

RSV epidemiology has changed significantly as a result of the COVID-19 pandemic. In fact, the RSV season in 2020 was short or non-existent in many areas, with only a few cases. Trial recruitment had largely halted while many COVID-19 vaccination protocols were being developed. RSV season in the United States is generally assumed to start in October and peak between late December and mid-February, but that changed at a later date. The CDC has noticed that a recent increase in RSV cases, which is usually rarely seen in the summer, has dramatically changed the RSV research environment. While the COVID-19 pandemic has pushed vaccine development to the fore, it has also slowed clinical research in several therapeutic areas, such as RSV.

Major Players of Global Respiratory Syncytial Virus Vaccines and Antibodies Market are

  • Johnson & Johnson

  • Pfizer

  • GlaxoSmithKline

  • Astra Zeneca

  • Merck & Co.

  • Sanofi

  • Bavarian Nordic

  • Modern

  • Meissa vaccines

  • Advaccination

  • Codagenix

Main topics covered:

1. Summary

2. Presentation

2.1 RSV vaccine and antibodies: an overview

2.2 Segmentation of RSV Vaccine and Antibodies

3. Global Market Analysis

3.1 Global RSV Vaccines and Antibodies Market: An Analysis

3.2 Global RSV Vaccines and Antibodies Market: End User Analysis

3.3 Global RSV Vaccines and Antibodies Market: Type Analysis

3.4 Global RSV Vaccines Market: End User Analysis

4. Regional Market Analysis

4.1 The US market for RSV vaccines and antibodies

4.2 Europe RSV Vaccines and Antibodies Market

4.3 RSV Vaccines and Antibodies Market ROW

5. Impact of COVID-19

5.1 Impact of COVID-19

5.1.1 Impact of COVID-19 on healthcare

5.1.2 Impact of COVID-19 restrictions on RSV transmission

5.1.3 Impact of COVID-19 on the RSV Vaccines and Antibodies Market

6. Market dynamics

6.1 Drivers of growth

6.1.1 Rapid urbanization

6.1.2 Increase in the geriatric population

6.1.3 Increase in health expenditure

6.1.4 Increasing prevalence of respiratory syncytial virus

6.1.5 Greatest unmet need

6.1.6 Increase in RSV cases in infants

6.1.7 Favorable government support

6.2 Challenges

6.2.1 High cost of vaccine development

6.2.2 Inequitable access to vaccines

6.3 Market trends

6.3.1 Use of AI in vaccine and drug design

6.3.2 Technological Advances in Vaccine Delivery

6.3.3 Competitive pipeline

7. Competitive Landscape

7.1 Global RSV Vaccines and Antibodies Market: Vaccine and Antibody Candidates

7.2 Global RSV Vaccine and Antibodies Players by Market Share

7.3 Global RSV Vaccines and Antibodies Market: Current Landscape

8. Company Profiles

For more information on this report, visit https://www.researchandmarkets.com/r/6r0jtq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Comments are closed.